Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
488
Employees488
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
488
Employees488

AGIO Key Statistics

Market cap
1.60B
Market cap1.60B
Price-Earnings ratio
-3.94
Price-Earnings ratio-3.94
Dividend yield
Dividend yield
Average volume
2.59M
Average volume2.59M
High today
$27.68
High today$27.68
Low today
$27.13
Low today$27.13
Open price
$27.25
Open price$27.25
Volume
1.23M
Volume1.23M
52 Week high
$62.45
52 Week high$62.45
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

With a market cap of 1.6B, Agios(AGIO) trades at $27.68. The stock has a price-to-earnings ratio of -3.94.

On 2025-12-04, Agios(AGIO) stock traded between a low of $27.13 and a high of $27.68. Shares are currently priced at $27.68, which is +2.0% above the low and 0.0% below the high.

The Agios(AGIO)'s current trading volume is 1.23M, compared to an average daily volume of 2.59M.

During the past year, Agios(AGIO) stock moved between $22.24 at its lowest and $62.45 at its peak.

During the past year, Agios(AGIO) stock moved between $22.24 at its lowest and $62.45 at its peak.

AGIO News

Simply Wall St 1d
Why Agios Pharmaceuticals Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat

In November 2025, Agios Pharmaceuticals reported positive topline data from its global Phase 3 RISE UP trial, showing that mitapivat achieved a statistically si...

Why Agios Pharmaceuticals Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat
Simply Wall St 6d
A Look at Agios Pharmaceuticals Valuation Following Strong Phase 3 Sickle Cell Trial Results

Agios Pharmaceuticals (AGIO) just released topline results from its RISE UP Phase 3 trial of mitapivat in sickle cell disease. The study achieved its primary ef...

A Look at Agios Pharmaceuticals Valuation Following Strong Phase 3 Sickle Cell Trial Results

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.